Loading organizations...
§ Private Profile · San Diego, CA, USA
NanoCellect Biomedical is a technology company.
NanoCellect Biomedical has raised $45.3M across 4 funding rounds.
Key people at NanoCellect Biomedical.
NanoCellect Biomedical has raised $45.3M in total across 4 funding rounds.
NanoCellect is committed to empowering every scientist to make discoveries one cell at a time, with modern and simple technologies for to advance cell based assays that are affordable, compact, and easy-to-use.
NanoCellect Biomedical has raised $45.3M in total across 4 funding rounds.
NanoCellect Biomedical's investors include Boehringer Ingelheim Venture Fund, Illumina Ventures, Leaps by Bayer, Paladin Capital Group, Anterra Capital, Genoa Ventures, Heavybit, Maverick Capital, Agilent Technologies, Anzu Partners, FusionX Ventures, Vertical Venture Partners.
Key people at NanoCellect Biomedical.
NanoCellect Biomedical has raised $45.3M across 4 funding rounds. Most recently, it raised $20.0M Series D in August 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Aug 1, 2021 | $20M Series D | — | Boehringer Ingelheim Venture Fund, Illumina Ventures, Leaps BY Bayer, Paladin Capital Group | Announced |
| Jan 1, 2021 | $15M Series C | — | Boehringer Ingelheim Venture Fund, Illumina Ventures, Leaps BY Bayer, Paladin Capital Group | Announced |
| Jan 1, 2018 | $250K Series U | — | Boehringer Ingelheim Venture Fund, Illumina Ventures | Announced |
| Nov 1, 2017 | $10M Series B | — | Anterra Capital, Boehringer Ingelheim Venture Fund, Genoa Ventures, Heavybit, Illumina Ventures, Maverick Capital, Agilent Technologies, Anzu Partners, FusionX Ventures, Vertical Venture Partners | Announced |
NanoCellect Biomedical is a San Diego-based biotechnology company founded in 2009 that develops and manufactures microfluidic cell sorters for biomedical research, enabling gentle, high-viability sorting of sensitive cells like stem cells, plant cells, and microbes.[1][2][3] Its flagship products, including the WOLF G2, VERLO Image-Guided Cell Sorter, and N1 Single-Cell Dispenser, serve researchers in academic labs, biotech/pharma companies, and hospitals by solving challenges in single-cell genomics, gene editing, antibody discovery, cell line development, and immuno-oncology workflows.[2][3][4][5] The company has raised $85.42M in funding, reaching Series E stage, with its last round of $28.93M about two years ago, reflecting strong growth momentum in the expanding single-cell analysis market driven by demand for sterile, reproducible results in cellular therapies.[1][4]
These benchtop systems prioritize ease-of-use—no expert operators needed—compact design, and disposable cartridges to minimize contamination, making advanced cell sorting accessible beyond large facilities.[2][3][8] NanoCellect targets pain points in traditional flow cytometry, such as cell damage and complexity, positioning it as a key enabler for drug discovery, diagnostics, and basic research.[3][4][9]
NanoCellect Biomedical, formerly known as NanoSort, was founded in 2009 in San Diego, California, by a team of scientists and engineers addressing limitations in traditional cell sorting technologies.[1][3] Co-founder and President Jose Morachis, PhD, played a pivotal role, drawing from expertise in microfluidics to create an intuitive platform that delivers high-quality results without requiring specialized training.[3][4] The idea emerged from the need for a modern alternative to bulky, expert-only flow cytometers, leveraging patented microfluidic chips for gentle handling of fragile samples like stem cells amid rising demands in single-cell applications and immuno-oncology.[3][4]
Early traction came from developing the WOLF Cell Sorter, which used proven detection tech with innovative, disposable cartridges to simplify workflows and ensure sterility—critical for markets like gene editing and antibody therapeutics.[3][4] This focus on accessibility propelled the company forward, evolving from basic microfluidic sorting to advanced models like the multi-laser WOLF G2 and imaging-enabled VERLO, while securing significant funding and adoption in diverse research fields.[1][3][7]
NanoCellect rides the single-cell analysis boom, fueled by advances in cellular therapies, immuno-oncology, and gene editing, where high-viability inputs are essential for reliable genomics and drug development.[1][4] Timing aligns with market growth: consumables like reagents dominated in 2023 due to reproducibility demands, while academic labs lead adoption amid rising cancer research funding.[1] Favorable forces include surging investments in life sciences and needs for sterile, portable tools in biotech/pharma, hospitals, and IVF centers.[1][4]
By democratizing flow cytometry, NanoCellect influences the ecosystem, enabling smaller players to innovate in antibody discovery and CRISPR without big-instrument barriers, accelerating breakthroughs in therapeutics and basic research.[3][4][9]
NanoCellect is poised for expansion with its Series E backing, likely advancing multi-parameter imaging (e.g., VERLO evolutions) and AI-enhanced sorting to capture more of the single-cell omics market.[1][3][5] Trends like immuno-oncology, cell/gene therapies, and microbial applications will shape its path, bolstered by consumables revenue from disposable chips.[1][2][4] Its influence may grow by integrating with NGS/PCR workflows, solidifying leadership in accessible, gentle cell tech and empowering broader biomedical discovery from the original WOLF innovation.[3][7]
